A recent Phase 2a trial in trigeminal neuralgia patients demonstrated that the selective NaV1.7 inhibitor BIIB074 produced fewer treatment failures than placebo and a better improvement in the daily pain score than placebo during the double-blind phase [57], results that are encouraging, but clearly larger trials are needed, especially those aimed at determining if BIIB074 is actually more efficacious and/or provides a lower side effect burden than the current first-line medications for trigeminal neuralgia, such as carbamazepine. The gene discussed is SCN9A; the disease is trigeminal nerve disorder.